Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55


Promising effects of xanthine oxidase inhibition by allopurinol on autonomic heart regulation estimated by heart rate variability (HRV) analysis in rats exposed to hypoxia and hyperoxia.

Zajączkowski S, Ziółkowski W, Badtke P, Zajączkowski MA, Flis DJ, Figarski A, Smolińska-Bylańska M, Wierzba TH.

PLoS One. 2018 Feb 12;13(2):e0192781. doi: 10.1371/journal.pone.0192781. eCollection 2018.


Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials.

Bredemeier M, Lopes LM, Eisenreich MA, Hickmann S, Bongiorno GK, d'Avila R, Morsch ALB, da Silva Stein F, Campos GGD.

BMC Cardiovasc Disord. 2018 Feb 7;18(1):24. doi: 10.1186/s12872-018-0757-9.


XOR inhibition with febuxostat accelerates pulmonary endothelial barrier recovery and improves survival in lipopolysaccharide-induced murine sepsis.

Damarla M, Johnston LF, Liu G, Gao L, Wang L, Varela L, Kolb TM, Kim BS, Damico RL, Hassoun PM.

Physiol Rep. 2017 Aug;5(15). pii: e13377. doi: 10.14814/phy2.13377.


Safety and effect of high dose allopurinol in patients with severe left ventricular systolic dysfunction.

Ansari-Ramandi MM, Maleki M, Alizadehasl A, Amin A, Taghavi S, Alemzadeh-Ansari MJ, Kazem Moussavi A, Naderi N.

J Cardiovasc Thorac Res. 2017;9(2):102-107. doi: 10.15171/jcvtr.2017.17. Epub 2017 May 17.


Impact of Oxidative Stress on the Heart and Vasculature: Part 2 of a 3-Part Series.

Münzel T, Camici GG, Maack C, Bonetti NR, Fuster V, Kovacic JC.

J Am Coll Cardiol. 2017 Jul 11;70(2):212-229. doi: 10.1016/j.jacc.2017.05.035. Review.


Xanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic review and meta-analysis.

Zhang J, Dierckx R, Mohee K, Clark AL, Cleland JG.

ESC Heart Fail. 2017 Feb;4(1):40-45. doi: 10.1002/ehf2.12112. Epub 2016 Sep 20.


The risk of atrial fibrillation in patients with gout: a nationwide population-based study.

Kuo YJ, Tsai TH, Chang HP, Chua S, Chung SY, Yang CH, Lin CJ, Wu CJ, Hang CL.

Sci Rep. 2016 Sep 7;6:32220. doi: 10.1038/srep32220.


Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies.

Bonsu KO, Owusu IK, Buabeng KO, Reidpath DD, Kadirvelu A.

Ther Clin Risk Manag. 2016 Jun 3;12:887-906. doi: 10.2147/TCRM.S106065. eCollection 2016. Review.


Cardiac progenitor cell-derived exosomes prevent cardiomyocytes apoptosis through exosomal miR-21 by targeting PDCD4.

Xiao J, Pan Y, Li XH, Yang XY, Feng YL, Tan HH, Jiang L, Feng J, Yu XY.

Cell Death Dis. 2016 Jun 23;7(6):e2277. doi: 10.1038/cddis.2016.181.


Antioxidants in Cardiovascular Therapy: Panacea or False Hope?

Goszcz K, Deakin SJ, Duthie GG, Stewart D, Leslie SJ, Megson IL.

Front Cardiovasc Med. 2015 Jul 6;2:29. doi: 10.3389/fcvm.2015.00029. eCollection 2015. Review.


Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study.

Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O'Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF; NHLBI Heart Failure Clinical Research Network.

Circulation. 2015 May 19;131(20):1763-71. doi: 10.1161/CIRCULATIONAHA.114.014536. Epub 2015 Apr 14.


Xanthine oxidase inhibitors in heart failure: where do we go from here?

Tamariz L, Hare JM.

Circulation. 2015 May 19;131(20):1741-4. doi: 10.1161/CIRCULATIONAHA.115.016379. Epub 2015 Apr 14. No abstract available.


Innate immunity and the failing heart: the cytokine hypothesis revisited.

Mann DL.

Circ Res. 2015 Mar 27;116(7):1254-68. doi: 10.1161/CIRCRESAHA.116.302317. Review.


Mitochondria as key targets of cardioprotection in cardiac ischemic disease: role of thyroid hormone triiodothyronine.

Forini F, Nicolini G, Iervasi G.

Int J Mol Sci. 2015 Mar 19;16(3):6312-36. doi: 10.3390/ijms16036312. Review.


Obligatory role of neuronal nitric oxide synthase in the heart's antioxidant adaptation with exercise.

Roof SR, Ho HT, Little SC, Ostler JE, Brundage EA, Periasamy M, Villamena FA, Györke S, Biesiadecki BJ, Heymes C, Houser SR, Davis JP, Ziolo MT.

J Mol Cell Cardiol. 2015 Apr;81:54-61. doi: 10.1016/j.yjmcc.2015.01.003. Epub 2015 Jan 14.


Targeted antioxidant treatment decreases cardiac alternans associated with chronic myocardial infarction.

Plummer BN, Liu H, Wan X, Deschênes I, Laurita KR.

Circ Arrhythm Electrophysiol. 2015 Feb;8(1):165-73. doi: 10.1161/CIRCEP.114.001789. Epub 2014 Dec 9.


Abnormal Ca(2+) cycling in failing ventricular myocytes: role of NOS1-mediated nitroso-redox balance.

Ziolo MT, Houser SR.

Antioxid Redox Signal. 2014 Nov 10;21(14):2044-59. doi: 10.1089/ars.2014.5873. Epub 2014 Aug 7. Review.


Comorbidities in patients with crystal diseases and hyperuricemia.

Sattui SE, Singh JA, Gaffo AL.

Rheum Dis Clin North Am. 2014 May;40(2):251-78. doi: 10.1016/j.rdc.2014.01.005. Epub 2014 Feb 19. Review.


Incorporating common biomarkers into the clinical management of heart failure.

Halkar M, Tang WH.

Curr Heart Fail Rep. 2013 Dec;10(4):450-7. doi: 10.1007/s11897-013-0165-5. Review.


Oxidized Ca(2+)/calmodulin-dependent protein kinase II triggers atrial fibrillation.

Purohit A, Rokita AG, Guan X, Chen B, Koval OM, Voigt N, Neef S, Sowa T, Gao Z, Luczak ED, Stefansdottir H, Behunin AC, Li N, El-Accaoui RN, Yang B, Swaminathan PD, Weiss RM, Wehrens XH, Song LS, Dobrev D, Maier LS, Anderson ME.

Circulation. 2013 Oct 15;128(16):1748-57. doi: 10.1161/CIRCULATIONAHA.113.003313. Epub 2013 Sep 12.

Supplemental Content

Support Center